AMABILE, MARILINA
AMABILE, MARILINA
DIPARTIMENTO DI EMATOLOGIA E SCIENZE ONCOLOGICHE "L. e A. SERAGNOLI"
M. Amabile; AMABILE M
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia
2005 Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M.
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
2006 Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate.
2008 Bocchia M; Ippoliti M; Gozzetti A; Abruzzese E; Calabrese S; Amabile M; Pirrotta MT; Crupi R; Tozzuoli D; Trawinska MM; Defina M; Martinelli G; Lauria F.
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
2006 IACOBUCCI I; ROSTI G; AMABILE M; POERIO A; SOVERINI S; CILLONI D; TESTONI N; ABRUZZESE E; MONTEFUSCO E; OTTAVIANI E; IULIANO F; RUSSO D; GOBBI M; ALIMENA G; MARTINO B; TERRAGNA C; PANE F; SAGLIO G; BACCARANI M; MARTINELLI G
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia
2006 Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G; on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML)
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis
2010 Castagnetti F; Testoni N;Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A;Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib
2004 SOVERINI S; MARTINELLI G.; AMABILE M; POERIO A; BIANCHINI M; ROSTI G; PANE F; SAGLIO G; BACCARANI M.
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes.
2006 Catani L.; Fagioli M.E.; Tazzari P.L.; Ricci F.; Curti A.; Rovito M.; Preda P.; Chirumbolo G.; Amabile M.; Lemoli R.M.; Tura S.; Conte R.; Baccarani M.; Vianelli N.
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia
2004 PICCALUGA PP; MALAGOLA M; RONDONI M; AMABILE M; PAOLINI S; SOVERINI S; GAITANI S; VISANI G; BACCARANI M.; MARTINELLI G
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience
2009 Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandra; Lonetti, Annalisa; Baldazzi, Carmen; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Castagnetti, Fausto; Poerio, Angela; Clissa, Cristina; Parisi, Sarah; Polverelli, Nicola; Guadagnuolo, Viviana; Pier Paolo Piccaluga, ; Rosti, Gianantonio; Baccarani, Michele; Martinelli, Giovanni
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience
2010 Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandra; Lonetti, Annalisa; Ferrari, Anna; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Clissa, Cristina; Parisi, Sarah; Guadagnuolo, Viviana; Baccarani, Michele; Martinelli, Giovanni
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
2008 Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML.
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.
2011 Gugliotta G.; Castagnetti F.; Palandri F.; Breccia M.; Intermesoli T.; Capucci A.; Martino B.; Pregno P.; Rupoli S.; Ferrero D.; Gherlinzoni F.; Montefusco E.; Bocchia M.; Tiribelli M.; Pierri I.; Grifoni F.; Marzocchi G.; Amabile M.; Testoni N.; Martinelli G.; Alimena G.; Pane F.; Saglio G.; Baccarani M.; Rosti G.
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION
2009 Colarossi, S.; Gnani, A.; Soverini, S.; Castagnetti, F.; Marzocchi, G.; Luatti, S.; Astolfi, A.; Formica, S.; Iacobucci, I.; Lonetti, A.; Palandri, F.; Poerio, A.; Amabile, M.; Rosti, G.; Pession, A.; Testoni, N.; Baccarani, M.; Martinelli, G.
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
2004 BACCARANI M.; MARTINELLI G.; ROSTI G.; TRABACCHI E.; TESTONI N.; BASSI S.; AMABILE M.; SOVERINI S.; CASTAGNETTI F.; CILLONI D.; IZZO B.; DE VIVO A.; MESSA E.; BONIFAZI F.; POERIO A.; LUATTI S.; GIUGLIANO E.; ALBERTI D.; FINCATO G.; RUSSO D.; PANE F.; SAGLIO G.; GIMEMA WORKING PARTY ON CHRONIC MYELOID LEUKEMIA
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP.
2005 Iacobucci, I; Testoni, N; Rosti, G; Amabile, M; Poerio, A; Soverini, S; Colarossi, S; Gnani, A; Ottaviani, E; Castagnetti, F; Terragna, C; Renzulli, M; Grafone, T; Cilloni, D; Pane, F; Saglio, G; Baccarani, M; Martinelli, G
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
2005 Malagola M; Martinelli G; Rondoni M; Paolini S; Gaitani S; Arpinati M; Piccaluga PP; Amabile M; Basi C; Ottaviani E; Candoni A; Gottardi E; Cilloni D; Bocchia M; Saglio G; Lauria F; Fanin R; Visani G; Marre MC; Maderna M; Rancati F; Vinaccia V; Russo D; Baccarani M.
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
2007 Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia | Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagn...etti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M. | 2005-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. | Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cill...oni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G | 2006-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies | Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.;... Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G. | 2006-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. | Bocchia M; Ippoliti M; Gozzetti A; Abruzzese E; Calabrese S; Amabile M; Pirrotta MT; Crupi R; Toz...zuoli D; Trawinska MM; Defina M; Martinelli G; Lauria F. | 2008-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. | IACOBUCCI I; ROSTI G; AMABILE M; POERIO A; SOVERINI S; CILLONI D; TESTONI N; ABRUZZESE E; MONTEFU...SCO E; OTTAVIANI E; IULIANO F; RUSSO D; GOBBI M; ALIMENA G; MARTINO B; TERRAGNA C; PANE F; SAGLIO G; BACCARANI M; MARTINELLI G | 2006-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia | Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruz...zese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G; on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML) | 2006-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis |
Castagnetti F; Testoni N;Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo... A;Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G |
2010-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib | SOVERINI S; MARTINELLI G.; AMABILE M; POERIO A; BIANCHINI M; ROSTI G; PANE F; SAGLIO G; BACCARANI M. | 2004-01-01 | CLINICAL CHEMISTRY | - | 1.01 Articolo in rivista | - |
| Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. | Catani L.; Fagioli M.E.; Tazzari P.L.; Ricci F.; Curti A.; Rovito M.; Preda P.; Chirumbolo G.; Am...abile M.; Lemoli R.M.; Tura S.; Conte R.; Baccarani M.; Vianelli N. | 2006-01-01 | EXPERIMENTAL HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia | PICCALUGA PP; MALAGOLA M; RONDONI M; AMABILE M; PAOLINI S; SOVERINI S; GAITANI S; VISANI G; BACCA...RANI M.; MARTINELLI G | 2004-01-01 | EUROPEAN JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies | Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.;... Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G. | 2006-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience | Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandr...a; Lonetti, Annalisa; Baldazzi, Carmen; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Castagnetti, Fausto; Poerio, Angela; Clissa, Cristina; Parisi, Sarah; Polverelli, Nicola; Guadagnuolo, Viviana; Pier Paolo Piccaluga, ; Rosti, Gianantonio; Baccarani, Michele; Martinelli, Giovanni | 2009-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience | Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandr...a; Lonetti, Annalisa; Ferrari, Anna; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Clissa, Cristina; Parisi, Sarah; Guadagnuolo, Viviana; Baccarani, Michele; Martinelli, Giovanni | 2010-01-01 | CANCER RESEARCH | - | 4.02 Riassunto (Abstract) | - |
| Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome | Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T,... Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML. | 2008-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. | Gugliotta G.; Castagnetti F.; Palandri F.; Breccia M.; Intermesoli T.; Capucci A.; Martino B.; Pr...egno P.; Rupoli S.; Ferrero D.; Gherlinzoni F.; Montefusco E.; Bocchia M.; Tiribelli M.; Pierri I.; Grifoni F.; Marzocchi G.; Amabile M.; Testoni N.; Martinelli G.; Alimena G.; Pane F.; Saglio G.; Baccarani M.; Rosti G. | 2011-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION | Colarossi, S.; Gnani, A.; Soverini, S.; Castagnetti, F.; Marzocchi, G.; Luatti, S.; Astolfi, A.; ...Formica, S.; Iacobucci, I.; Lonetti, A.; Palandri, F.; Poerio, A.; Amabile, M.; Rosti, G.; Pession, A.; Testoni, N.; Baccarani, M.; Martinelli, G. | 2009-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia | BACCARANI M.; MARTINELLI G.; ROSTI G.; TRABACCHI E.; TESTONI N.; BASSI S.; AMABILE M.; SOVERINI S....; CASTAGNETTI F.; CILLONI D.; IZZO B.; DE VIVO A.; MESSA E.; BONIFAZI F.; POERIO A.; LUATTI S.; GIUGLIANO E.; ALBERTI D.; FINCATO G.; RUSSO D.; PANE F.; SAGLIO G.; GIMEMA WORKING PARTY ON CHRONIC MYELOID LEUKEMIA | 2004-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. | Iacobucci, I; Testoni, N; Rosti, G; Amabile, M; Poerio, A; Soverini, S; Colarossi, S; Gnani, A; O...ttaviani, E; Castagnetti, F; Terragna, C; Renzulli, M; Grafone, T; Cilloni, D; Pane, F; Saglio, G; Baccarani, M; Martinelli, G | 2005-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? | Malagola M; Martinelli G; Rondoni M; Paolini S; Gaitani S; Arpinati M; Piccaluga PP; Amabile M; B...asi C; Ottaviani E; Candoni A; Gottardi E; Cilloni D; Bocchia M; Saglio G; Lauria F; Fanin R; Visani G; Marre MC; Maderna M; Rancati F; Vinaccia V; Russo D; Baccarani M. | 2005-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. | Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin ...R; Martinelli G; Baccarani M. | 2007-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |